SCS
HZNP

Syquant Capital SAS’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Syquant Capital SAS’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,398,990
Closed -$162M – 14
2023
Q3 		$162M Buy
1,398,990
+545,824
+64% +$58.6M 63.55% 1
2023
Q2 		$87.7M Buy
853,166
+581,549
+214% +$61.4M 63.76% 1
2023
Q1 		$29.6M Buy
+271,617
New +$30M 68.69% 1

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Syquant Capital SAS's HZNP Position: Q4 2023 in Review

Syquant Capital SAS sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 1,398,990 shares — an estimated $162M sold.

Syquant Capital SAS first reported a position in HZNP in Q1 2023 and held it in 3 quarters. The position peaked at $162M in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Syquant Capital SAS reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Syquant Capital SAS sold 1,398,990 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $162M.
  • Syquant Capital SAS first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2023 and held it in 3 quarters.
  • Syquant Capital SAS's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $162M in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Syquant Capital SAS's 13F filing for Q4 2023, filed 10 Jan 2024.